Global phase III trial of comparing mXELIRI+BV vs FOLFIRI+Bmab for 2nd line mCRC (AXEPT) Japanese population analysis

Takeshi Kato, Yoshinori Kagawa, Mitsuyoshi Ota, Akitaka Makiyama, Tadamichi Denda, Chu Matsuda, Yasuhide Yamada, Satoru Iwasa, Tae Won Kim, Rui Hua Xu, Young Suk Park, Satoshi Morita, Junichi Sakamoto, Kei Muro

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)vii51
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - 1 Oct 2018

Cite this

Kato, T., Kagawa, Y., Ota, M., Makiyama, A., Denda, T., Matsuda, C., Yamada, Y., Iwasa, S., Won Kim, T., Xu, R. H., Suk Park, Y., Morita, S., Sakamoto, J., & Muro, K. (2018). Global phase III trial of comparing mXELIRI+BV vs FOLFIRI+Bmab for 2nd line mCRC (AXEPT) Japanese population analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 29, vii51. https://doi.org/10.1093/annonc/mdy374.001